DE69431060D1 - Klonierte glutaminsäure-decarboxylase - Google Patents

Klonierte glutaminsäure-decarboxylase

Info

Publication number
DE69431060D1
DE69431060D1 DE69431060T DE69431060T DE69431060D1 DE 69431060 D1 DE69431060 D1 DE 69431060D1 DE 69431060 T DE69431060 T DE 69431060T DE 69431060 T DE69431060 T DE 69431060T DE 69431060 D1 DE69431060 D1 DE 69431060D1
Authority
DE
Germany
Prior art keywords
glutamic acid
acid decarboxylase
cloned
cloned glutamic
gad
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69431060T
Other languages
English (en)
Other versions
DE69431060T2 (de
Inventor
J Tobin
G Erlander
L Kaufman
J Clare-Salzler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of DE69431060D1 publication Critical patent/DE69431060D1/de
Application granted granted Critical
Publication of DE69431060T2 publication Critical patent/DE69431060T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01015—Glutamate decarboxylase (4.1.1.15)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rehabilitation Therapy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
DE69431060T 1993-09-17 1994-08-24 Klonierte glutaminsäure-decarboxylase Expired - Lifetime DE69431060T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/123,859 US5674978A (en) 1990-09-21 1993-09-17 Peptides derived from glutamic acid decarboxylase
PCT/US1994/009478 WO1995007992A2 (en) 1993-09-17 1994-08-24 Cloned glutamic acid decarboxylase

Publications (2)

Publication Number Publication Date
DE69431060D1 true DE69431060D1 (de) 2002-08-29
DE69431060T2 DE69431060T2 (de) 2002-11-14

Family

ID=22411325

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69431060T Expired - Lifetime DE69431060T2 (de) 1993-09-17 1994-08-24 Klonierte glutaminsäure-decarboxylase

Country Status (11)

Country Link
US (5) US5674978A (de)
EP (1) EP0719340B1 (de)
JP (1) JP3133339B2 (de)
KR (1) KR100367943B1 (de)
AT (1) ATE221125T1 (de)
AU (1) AU697058B2 (de)
CA (1) CA2170523C (de)
DE (1) DE69431060T2 (de)
DK (1) DK0719340T3 (de)
ES (1) ES2179077T3 (de)
WO (1) WO1995007992A2 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE268908T1 (de) 1990-09-07 2004-06-15 Univ California Verfahren zur diagnose und behandlung von diabetes
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
US6682906B1 (en) * 1990-09-21 2004-01-27 The Regents Of The University Of California Cloned glutamic acid decarboxylase
IL101872A0 (en) * 1991-05-15 1992-12-30 Univ Washington Cloning and expression of human islet glutamic acid decarboxylase autoantigen
ES2318847T3 (es) * 1992-12-03 2009-05-01 The Regents Of The University Of California Metodos y reactivos mejorados para el diagnostico y el tratamiento de diabetes y del sindrome de stiff man.
CN1112933A (zh) * 1994-01-20 1995-12-06 伯伦格·曼海姆有限公司 抗原特异性活化t淋巴细胞，其检测和用途
DE69637130T2 (de) * 1995-02-20 2008-02-21 The Walter And Eliza Hall Institute Of Medical Research, Parkville Immunoreaktive und immunotherapeutische moleküle welche in individuen mit insulin-abhängiger diabetes mellitus interagieren
US5840307A (en) * 1995-03-31 1998-11-24 Immulogic Pharmacuetical Corp. Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation
US5945401A (en) * 1995-06-23 1999-08-31 Conlon; Paul J. Peptide analogues of the 65KD isoform of human glutamic acid decarboxylase and uses thereof
DE19525784A1 (de) * 1995-07-14 1997-01-16 Boehringer Mannheim Gmbh Autoreaktive Peptide aus der humanen Glutamin-Decarboxylase (GAD)
DE19526561A1 (de) * 1995-07-20 1997-01-23 Boehringer Mannheim Gmbh In-vivo-Diabetes-Test
WO1997036618A1 (fr) * 1996-04-01 1997-10-09 Chugai Seiyaku Kabushiki Kaisha Composition diagnostique pour maladies s'accompagnant de reactions auto-immunes declenchees par la decarboxylase d'acide 65k-glutamique
US7361331B2 (en) 1996-10-18 2008-04-22 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food Plant bioreactors
US6815174B1 (en) * 1996-11-28 2004-11-09 Edgardo Poskus Thioredoxin-glutamate decarboxylase 65 fusion protein
FR2759701B1 (fr) * 1997-02-19 1999-06-04 Inst Nat Sante Rech Med Utilisation des proteines ulip dans le diagnostic et la therapie des cancers et des syndromes neurologiques paraneoplasiques
WO1999020295A1 (en) * 1997-10-17 1999-04-29 Trustees Of The University Of Pennsylvania Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator
SE9704451D0 (sv) * 1997-11-28 1997-11-28 Diamyd Therapeutics Ab New method and compositions for the treatment of autoimmune diseases
WO1999037315A1 (en) * 1998-01-27 1999-07-29 Bai Jane Pei Fan Chemical derivatives of autoantigens and autoimmune-suppressive peptides and pharmaceutical composition containing the same
US6303325B1 (en) 1998-05-29 2001-10-16 Dade Behring Inc. Method for detecting analytes
US6232082B1 (en) 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction
AU775484C (en) * 1999-08-23 2005-02-17 Benaroya Research Institute At Virginia Mason Peptide and peptide analogues for the treatment and prevention of diabetes
US6436401B1 (en) 1999-09-14 2002-08-20 Milkhaus Laboratory, Inc. Methods for alleviating symptoms associated with diabetes and diabetic neuropathy comprising administration of low levels of antibodies
US6713058B2 (en) * 1999-09-14 2004-03-30 Milkhaus Laboratory, Inc. Methods for alleviating symptoms associated with neuropathic conditions comprising administration of low levels of antibodies
EP1149914B1 (de) * 2000-04-10 2008-06-18 Labor Dr. Merk und Kollegen GmbH Fusionsprotein zur gleichzeitigen Erkennung von humanen Autoantikörpern
US6645725B2 (en) 2000-04-19 2003-11-11 Research Corporation Technologies, Inc. Diagnostic assay for endometriosis
US7178152B2 (en) * 2001-03-01 2007-02-13 Sony Corporation Application programming interface for communication between audio/video file system and audio video controller
CA2443777A1 (en) * 2001-04-10 2002-10-24 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic and diagnostic uses of antibody specificity profiles
US20050130245A1 (en) * 2001-09-17 2005-06-16 Syn X Pharma, Inc. Diagnosis and treatment of early pre-type-1 diabetes utilizing neuronal proteins
US20050004001A1 (en) * 2002-10-02 2005-01-06 Robert Harris Formulation of antigen
WO2005102374A2 (en) * 2004-03-03 2005-11-03 Diamyd Medical Ab Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
US20050250691A1 (en) * 2004-05-10 2005-11-10 Diamyd Therapeutics Ab Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
US20050209138A1 (en) * 2004-03-19 2005-09-22 Diamyd Therapeutics Ab Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
WO2007114959A2 (en) * 2006-04-04 2007-10-11 University Of Toledo Altered peptide ligands of gad65
CN100450552C (zh) * 2006-05-26 2009-01-14 中国医学科学院医学生物学研究所 Ⅰ型糖尿病疫苗及其构建方法
WO2008016629A2 (en) * 2006-08-01 2008-02-07 Neurologix, Inc. Novel glutamic acid decarboxylase (gad) proteins and methods of use
US20100279422A1 (en) * 2006-08-21 2010-11-04 Cmed Technologies Ltd. Method of surface plasmon resonance (spr) technology to detect genomic disorders for prenatal diagnosis
WO2008036465A2 (en) * 2006-09-18 2008-03-27 CMED Technologies Ltd. Office of Walkers Limited A method to assess cancer susceptibility and differential diagnosis of metastases of unknown primary tumors
WO2008036470A2 (en) * 2006-09-19 2008-03-27 Cmed Technologies Ltd. A method for screening of infectious agents in blood
WO2008070223A2 (en) * 2006-09-21 2008-06-12 Cmed Technologies Ltd. A method to remove repetitive sequences from human dna
US20100047815A1 (en) * 2006-09-21 2010-02-25 Cmed Technologies Ltd. Method to detect tumor markers and diagnosis of undifferentiated tumors
WO2008085554A2 (en) * 2006-09-25 2008-07-17 Cmed Technologies Ltd. A method to detect virus related immunologigal markers for the diagnosis of hepatitis b virus infection
GB2455929B (en) * 2006-09-25 2011-08-31 Cmed Technologies Limited A method for the identification of human immunodeficiency virus related antibodies in blood
US20100041018A1 (en) * 2006-09-25 2010-02-18 Cmed Technologies Ltd. Method to detect virus related immunological markers for the diagnosis of hepatitis c virus infection
US20090311699A1 (en) * 2006-09-25 2009-12-17 Cmed Technologies Ltd. Method of surface plasmon resonance (spr) to detect genomic aberrations in patients with chronic lymphocytic leukemia
US8119350B2 (en) * 2006-09-25 2012-02-21 Cmed Technologies Ltd Method of surface plasmon resonance (SPR) to detect genomic aberrations in patients with multiple myeloma
US20100047789A1 (en) * 2006-09-25 2010-02-25 Cmed Technologies Ltd. Method of surface plasmon resonance (spr) to detect genomic disorders for postnatal diagnosis
WO2008067008A2 (en) * 2006-09-27 2008-06-05 Cmed Technologies Ltd. A method for the quantitative evaluation of sex hormones in a serum sample
US20100086937A1 (en) * 2006-09-27 2010-04-08 Cmed Technologies Ltd. method to detect treponema pallidum immunological markers for the diagnosis of syphilis
US20100021930A1 (en) * 2006-09-27 2010-01-28 Cmed Technologies Ltd. Application of surface plasmon resonance technology to maternal serum screening for congenital birth defects
WO2008067003A2 (en) * 2006-09-27 2008-06-05 Cmed Technologies Ltd. A method to detect virus related immunological markers for the diagnosis of respiratory tract infections
US20100004872A1 (en) * 2006-09-27 2010-01-07 Cmed Technologies Ltd. Method for quantitative measurement of cardiac biochemical markers
WO2008070241A2 (en) * 2006-09-27 2008-06-12 Cmed Technologies Ltd. A method to measure serum biomarkers for the diagnosis of liver fibrosis
WO2008067007A2 (en) * 2006-09-28 2008-06-05 Cmed Technologies Ltd. A method for quantitative measurement of thyroid homrones and related antibodies in a serum sample
US8110408B2 (en) * 2006-09-28 2012-02-07 Cmed Technologies Ltd. Method for quantitative detection of diabetes related immunological markers
WO2008111634A1 (ja) * 2007-03-15 2008-09-18 Reverse Proteomics Research Institute Co., Ltd. 脳・神経に特異的あるいは神経分化に特異的なバイオマーカー
PL2137315T3 (pl) 2007-03-16 2015-02-27 Genomatica Inc Kompozycje i sposoby do biosyntezy 1,4-butanodiolu i jego prekursorów
EP2146741A4 (de) * 2007-04-24 2010-08-04 Diamyd Therapeutics Ab Medikamente und verfahren zur behandlung von autoimmunerkrankungen und krebs
US7947483B2 (en) 2007-08-10 2011-05-24 Genomatica, Inc. Methods and organisms for the growth-coupled production of 1,4-butanediol
WO2009045216A1 (en) 2007-10-04 2009-04-09 Cmed Technologies Ltd. Application of surface plasmon resonance technology for detecting and genotyping hpv
WO2010030711A2 (en) * 2008-09-10 2010-03-18 Genomatica, Inc. Microorganisms for the production of 1,4-butanediol
CN105079781B (zh) 2008-11-30 2018-07-20 免疫桑特公司 用于治疗乳糜泻的组合物和方法
HUE031827T2 (en) 2009-06-04 2017-08-28 Genomatica Inc A method for separating the ingredients of a fermentation soup
CN113528417A (zh) 2009-06-04 2021-10-22 基因组股份公司 生产1,4-丁二醇的微生物和相关方法
CN105441374A (zh) 2009-10-13 2016-03-30 基因组股份公司 生产1,4-丁二醇、4-羟基丁醛、4-羟基丁酰-coa、腐胺和相关化合物的微生物及其相关方法
US8530210B2 (en) 2009-11-25 2013-09-10 Genomatica, Inc. Microorganisms and methods for the coproduction 1,4-butanediol and gamma-butyrolactone
US8048661B2 (en) 2010-02-23 2011-11-01 Genomatica, Inc. Microbial organisms comprising exogenous nucleic acids encoding reductive TCA pathway enzymes
US8637286B2 (en) 2010-02-23 2014-01-28 Genomatica, Inc. Methods for increasing product yields
EP2836845B1 (de) 2012-04-13 2018-05-09 DiabetOmics, Inc. Biomarker für schwangerschaftsdiabetes
BR112014030202A2 (pt) 2012-06-04 2017-09-12 Genomatica Inc microorganismos e métodos para a produção de 4-hidroxibutirato 1,4-butanodiol e compostos relacionados
EP3043812A1 (de) 2013-09-10 2016-07-20 Immusant Inc. Dosierung einer glutenpeptidzusammensetzung
EP3760224A3 (de) * 2014-06-04 2021-03-31 Diamyd Medical AB Neuartige kombinationen für antigenbasierte therapie
CA2962933A1 (en) 2014-09-29 2016-04-07 Immusant, Inc. Use of hla genetic status to assess or select treatment of celiac disease
CN107531767A (zh) 2014-11-21 2018-01-02 免疫桑特公司 用于在治疗和诊断1型糖尿病中使用的肽
TWI655812B (zh) 2016-07-20 2019-04-01 松下知識產權經營股份有限公司 懸吊型插座
GB202210967D0 (en) * 2022-07-27 2022-09-07 Univ Birmingham Tolerogenic peptides i

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4624926A (en) * 1981-01-02 1986-11-25 The Research Foundation Of State University Of New York Novel cloning vehicles for polypeptide expression in microbial hosts
US4487830A (en) * 1982-05-14 1984-12-11 American Hoechst Corporation Enzyme/immunofluorescent assay for autoantibodies
EP0138854B1 (de) * 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigen aktive aminosäuresequenzen
US4751181A (en) * 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
US6001360A (en) * 1988-12-13 1999-12-14 University Of Florida Method and compositions for early detection and treatment of insulin dependent diabetes mellitus
US5645998A (en) * 1988-12-13 1997-07-08 University Of Florida Research Foundation Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
US5762937A (en) * 1988-12-13 1998-06-09 University Of Florida Research Foundation, Inc. Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
AU4815890A (en) * 1988-12-13 1990-07-10 University Of Florida Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
US5227159A (en) * 1989-01-31 1993-07-13 Miller Richard A Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies
NO306996B1 (no) * 1989-02-17 2000-01-24 Bayer Ag Isolert bukspyttkjerteloey-celle-(ICA)-antigen for in vitro- bruk
US5114844A (en) * 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
AU661828B2 (en) * 1990-08-17 1995-08-10 University Of Florida Methods and compositions for early detection and treatment of insulin dependent diabetes mellitus
US5512447A (en) * 1990-09-07 1996-04-30 The Regents Of The University Of California Methods for the diagnosis and treatment of diabetes
US5475086A (en) * 1990-09-21 1995-12-12 The Regents Of The University Of California Cloned glutamic acid decarboxylase peptides
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
AU8864791A (en) * 1990-10-02 1992-04-28 Trigen Incorporated Antibodies and methods for diagnosis and treatment of diabetes
EP0572478B1 (de) * 1991-02-22 2005-09-07 The Walter And Eliza Hall Institute Of Medical Research Hbgad und higad polypeptide und nukleinsäuren und deren verwendung zur diagnose und behandlung von gad autoantigen assoziierten krankheiten
IL101872A0 (en) * 1991-05-15 1992-12-30 Univ Washington Cloning and expression of human islet glutamic acid decarboxylase autoantigen
AU661684B2 (en) * 1991-06-18 1995-08-03 Regents Of The University Of California, The Cloned glutamic acid decarboxylase
US5200318A (en) * 1992-05-13 1993-04-06 Miles Inc. Diagnosis of IDDM with a panel of immunoreagents
US5837477A (en) * 1993-01-15 1998-11-17 The United States Of America As Represented By The Department Of Health And Human Services T cell receptor ligands and methods of using same
EP0703783B1 (de) * 1993-03-05 2010-05-05 Epimmune Inc. Verfahren zur herstellung von immunogenen hla-a2.1-bindenden peptiden
US5547847A (en) * 1993-09-07 1996-08-20 University Of Washington Diagnosis of insulin-dependent diabetes

Also Published As

Publication number Publication date
CA2170523A1 (en) 1995-03-23
ES2179077T3 (es) 2003-01-16
EP0719340B1 (de) 2002-07-24
US5846740A (en) 1998-12-08
ATE221125T1 (de) 2002-08-15
US6011139A (en) 2000-01-04
US8926966B1 (en) 2015-01-06
US5674978A (en) 1997-10-07
US6455267B1 (en) 2002-09-24
JPH09503387A (ja) 1997-04-08
DE69431060T2 (de) 2002-11-14
KR100367943B1 (ko) 2003-06-18
DK0719340T3 (da) 2002-11-18
AU697058B2 (en) 1998-09-24
EP0719340A1 (de) 1996-07-03
AU7920194A (en) 1995-04-03
CA2170523C (en) 2010-03-30
WO1995007992A2 (en) 1995-03-23
JP3133339B2 (ja) 2001-02-05
KR960705051A (ko) 1996-10-09
WO1995007992A3 (en) 1995-06-22

Similar Documents

Publication Publication Date Title
DK0719340T3 (da) Klonet glutaminsyre-decarboxylase
CA2259163A1 (en) Nt-3 and bdnf analogs having improved circulating life and/or absorption
DE69731373D1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
AU1049788A (en) Methods and peptides for the treatment of non-ige-mediated diseases
EA199800946A1 (ru) Концентрированный препарат антител
WO1996019580A3 (en) Telomerase protein component
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
ATE396205T1 (de) Die verwendung von peptiden von il-2 und peptid- derivaten als therapeutische wirkstoffe
GB2367061A (en) Peptides
RU94041224A (ru) Пептиды с органозащитной активностью, фармацевтическая композиция на их основе и их применение в терапии
HUT66309A (en) Bpc peptides, their preparation and therapeutic use
ES2177625T3 (es) Citoquina cc-1 humana circulante.
ES2058479T3 (es) Compuestos peptidicos.
GB9311454D0 (en) Pharmaceutical compositions
AU1086888A (en) Primary biliary cirrhosis autoantigen
DK1431391T3 (da) RANTES-mutanter og terapeutiske anvendelser heraf
ATE110389T1 (de) Thf-zusammensetzungen.
FI960839A0 (fi) Uusia tripeptidejä, jotka ovat käyttökelpoisia immuuni- ja CNS-terapiassa
EP0317279A3 (de) Peptide für die Verwendung zur Reinigung von Faktor-VIII
DE68914397T2 (de) Menschliches Lymphotoxin.
MX9800239A (es) Metodos para el tratamiento y prevencion de diabetes.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition